Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30508578 | 1.00 | MEN1 (0.37) | MEN1KMT2ACYP2C9CYP2C19HSD17B10 | |
| SCHEMBL25310417 | 0.88 | TUBB4A (0.43) | KMT2ACYP2C9CYP2C19ALDH1A1KDM4E | |
| SCHEMBL31376398 | 0.87 | GABRP (0.37) | MEN1KMT2ACYP2C9CYP2C19ALDH1A1 | |
| SCHEMBL25867032 | 0.87 | MEN1 (0.36) | MEN1KMT2ACYP2C9CYP2C19HSD17B10 | |
| SCHEMBL25315898 | 0.87 | MEN1 (0.34) | MEN1KMT2ACYP2C9CYP2C19HSD17B10 | |
| SCHEMBL25944770 | 0.85 | PDE4B (0.34) | MEN1KMT2ACYP2C9CYP2C19HSD17B10 | |
| SCHEMBL25946388 | 0.84 | MEN1 (0.39) | MEN1KMT2ACYP2C9CYP2C19HSD17B10 | |
| SCHEMBL25942572 | 0.82 | HSD17B10 (0.50) | MEN1KMT2ACYP2C9CYP2C19HSD17B10 | |
| SCHEMBL25321658 | 0.82 | MEN1 (0.33) | MEN1KMT2ACYP2C9CYP2C19HSD17B10 | |
| SCHEMBL31078137 | 0.81 | RPS6KA5 (0.40) | MEN1KMT2ACYP2C9CYP2C19HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115607-A1 | PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-20240383875-A1 | Benzimidazole Pyridine Derivatives | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | disclosed |
| US-20240366581-A1 | BENZIMIDAZOLE PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| WO-2023139085-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023139085-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023139084-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383875-A1 | Benzimidazole Pyridine Derivatives | H1-3, H1-2, H1-4 | MEN1 1114/4885KMT2A 925/4885CYP2C9 120/4885 |
| US-20240366581-A1 | BENZIMIDAZOLE PYRIDINE DERIVATIVES | SIK3, JAK1, SIK2 | MEN1 3454/4885KMT2A 2032/4885CYP2C9 1715/4885 |
| US-20250115607-A1 | PYRIDINE DERIVATIVES | ADORA1, CYP1A1, MT-ND1 | MEN1 609/4885KMT2A 2509/4885CYP2C9 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.